GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Origin Therapeutics Holdings Inc (XCNQ:ORIG) » Definitions » Enterprise Value

Origin Therapeutics Holdings (XCNQ:ORIG) Enterprise Value : C$-3.65 Mil (As of May. 18, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Origin Therapeutics Holdings Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Origin Therapeutics Holdings's Enterprise Value is C$-3.65 Mil. Origin Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was C$-0.74 Mil. Therefore, Origin Therapeutics Holdings's EV-to-EBIT ratio for today is 4.91.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Origin Therapeutics Holdings's Enterprise Value is C$-3.65 Mil. Origin Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was C$-0.74 Mil. Therefore, Origin Therapeutics Holdings's EV-to-EBITDA ratio for today is 4.91.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Origin Therapeutics Holdings's Enterprise Value is C$-3.65 Mil. Origin Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was C$0.00 Mil. Therefore, Origin Therapeutics Holdings's EV-to-Revenue ratio for today is .


Origin Therapeutics Holdings Enterprise Value Historical Data

The historical data trend for Origin Therapeutics Holdings's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Origin Therapeutics Holdings Enterprise Value Chart

Origin Therapeutics Holdings Annual Data
Trend Sep21 Sep22
Enterprise Value
- -2.68

Origin Therapeutics Holdings Quarterly Data
Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Enterprise Value Get a 7-Day Free Trial Premium Member Only -1.58 -2.68 -3.93 -1.91 -1.65

Competitive Comparison of Origin Therapeutics Holdings's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Origin Therapeutics Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Origin Therapeutics Holdings's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Origin Therapeutics Holdings's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Origin Therapeutics Holdings's Enterprise Value falls into.



Origin Therapeutics Holdings Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Origin Therapeutics Holdings's Enterprise Value for the fiscal year that ended in Sep. 2022 is calculated as

Origin Therapeutics Holdings's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Origin Therapeutics Holdings  (XCNQ:ORIG) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Origin Therapeutics Holdings's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-3.649/-0.743
=4.91

Origin Therapeutics Holdings's current Enterprise Value is C$-3.65 Mil.
Origin Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.74 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Origin Therapeutics Holdings's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=-3.649/-0.743
=4.91

Origin Therapeutics Holdings's current Enterprise Value is C$-3.65 Mil.
Origin Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.74 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Origin Therapeutics Holdings's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-3.649/0
=

Origin Therapeutics Holdings's current Enterprise Value is C$-3.65 Mil.
Origin Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Origin Therapeutics Holdings Enterprise Value Related Terms

Thank you for viewing the detailed overview of Origin Therapeutics Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Origin Therapeutics Holdings (XCNQ:ORIG) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
505 Burrard Street, Suite 1570, Vancouver, BC, CAN, V7X 1M5
Origin Therapeutics Holdings Inc is an investment company focusing on investments in the psychedelic industry.

Origin Therapeutics Holdings (XCNQ:ORIG) Headlines

From GuruFocus

Ocean Rig UDW Inc Joins the Russell 3000® Index

By Marketwired Marketwired 06-26-2018

5 Energy Stocks in Gurus' Portfolios

By Tiziano Frateschi Tiziano Frateschi 06-01-2018

Bullish Developments Continue For Ocean Rig

By Faisal Humayun Faisal Humayun 06-30-2014

3 Reasons to Buy an Ocean Rig

By Subia Khan Value Investor 04-04-2014

Remain Cautious On Ocean Rig

By Faisal Humayun Faisal Humayun 04-16-2015